Please try another search
Breaking News
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1097 | 981 | 1097 | 1142 | 1390 | 1952 |
Fund Return | 9.69% | -1.87% | 9.69% | 4.53% | 6.81% | 6.92% |
Place in category | 452 | 379 | 452 | 311 | 371 | 186 |
% in Category | 19 | 17 | 19 | 17 | 23 | 15 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU0474970273 | 11.88B | 3.94 | -5.23 | 3.30 | ||
LU0474969937 | 11.88B | 5.83 | -3.51 | 5.13 | ||
Pictet Global Megatrend Selection e | 11.88B | 14.14 | 1.25 | 8.15 | ||
Pictet-Global Megatrend Sel HP EUR | 11.88B | 4.89 | -4.37 | 4.24 | ||
PIMegatrend Selection I EUR | 11.88B | 15.16 | 2.16 | 9.08 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund E Acc EUR | 22.58M | 14.87 | 3.61 | 4.82 | ||
European Growth Fund Y Acc EUR | 262.8M | 16.70 | 5.28 | 6.49 | ||
European Growth Fund Y DIST EUR | 67.07M | 16.70 | 5.28 | 6.49 | ||
European Growth Fund A DIST Eue | 6.83B | 15.73 | 4.38 | 5.61 | ||
European Growth Fund A Acc EUR | 166.45M | 15.77 | 4.40 | 5.61 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
HSBC | GB0005405286 | 4.38 | 840.20 | +0.53% | |
Novartis | CH0012005267 | 4.35 | 93.80 | +0.39% | |
Schneider Electric | FR0000121972 | 3.64 | 241.00 | +1.50% | |
Roche Holding Participation | CH0012032048 | 3.56 | 285.20 | +1.57% | |
Sanofi | FR0000120578 | 3.41 | 103.62 | +1.73% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
Summary | Strong Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review